Literature DB >> 8452578

Antirheumatic drugs: a proposed new classification.

J P Edmonds, D L Scott, D E Furst, P Brooks, H E Paulus.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8452578     DOI： 10.1002/art.1780360308

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  9 in total

Review 1.  Leflunomide: a review of its use in active rheumatoid arthritis.

Authors:  A Prakash; B Jarvis
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  Prognostic markers in rheumatoid arthritis and classification of antirheumatic therapies.

Authors:  E H Choy; D L Scott
Journal:  Drugs       Date:  1995       Impact factor: 9.546

3.  Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort.

Authors:  Veena K Ranganath; Jeonglim Yoon; Dinesh Khanna; Grace S Park; Daniel E Furst; David A Elashoff; Damini Jawaheer; John T Sharp; Richard H Gold; Edward C Keystone; Harold E Paulus
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

Review 4.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 5.  Methotrexate in rheumatoid arthritis. An update.

Authors:  B Bannwarth; L Labat; Y Moride; T Schaeverbeke
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 6.  Drug treatment of rheumatic diseases in the 1990s. Achievements and future developments.

Authors:  E H Choy; D L Scott
Journal:  Drugs       Date:  1997-03       Impact factor: 11.431

7.  A history of the term "DMARD".

Authors:  Jonas Kure Buer
Journal:  Inflammopharmacology       Date:  2015-05-23       Impact factor: 4.473

Review 8.  To stop the erosion of hope: the DMARD category and the place of semantics in modern rheumatology.

Authors:  Jonas Kure Buer
Journal:  Inflammopharmacology       Date:  2017-02-13       Impact factor: 4.473

9.  A systematic review of infliximab in the treatment of early rheumatoid arthritis.

Authors:  Sophie Martin Du Pan; Cem Gabay; Axel Finckh
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.